Is Zosano Pharma Corporation (NASDAQ:ZSAN) a Buy? The Stock Reported more Sellers

September 8, 2017 - By test

 Is Zosano Pharma Corporation (NASDAQ:ZSAN) a Buy? The Stock Reported more Sellers

The stock of Zosano Pharma Corporation (NASDAQ:ZSAN) registered an increase of 14.9% in short interest. ZSAN’s total short interest was 4.20M shares in September as published by FINRA. Its up 14.9% from 3.65M shares, reported previously. With 1.14M shares average volume, it will take short sellers 4 days to cover their ZSAN’s short positions. The short interest to Zosano Pharma Corporation’s float is 29.85%.

About 76,989 shares traded. Zosano Pharma Corp (NASDAQ:ZSAN) has declined 31.28% since September 8, 2016 and is downtrending. It has underperformed by 47.98% the S&P500.

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The company has market cap of $34.09 million. The Firm has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. It currently has negative earnings. The Company’s microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Zosano Pharma Corp (NASDAQ:ZSAN) Ratings Coverage

Among 3 analysts covering Zosano Pharma (NASDAQ:ZSAN), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Zosano Pharma had 5 analyst reports since September 29, 2015 according to SRatingsIntel. TH Capital maintained Zosano Pharma Corp (NASDAQ:ZSAN) on Tuesday, September 29 with “Buy” rating. TH Capital maintained Zosano Pharma Corp (NASDAQ:ZSAN) rating on Wednesday, November 11. TH Capital has “Buy” rating and $7 target. As per Tuesday, September 29, the company rating was maintained by Roth Capital. The rating was downgraded by Ladenburg Thalmann on Thursday, August 11 to “Neutral”. The stock has “Buy” rating by Roth Capital on Wednesday, November 11.

More notable recent Zosano Pharma Corp (NASDAQ:ZSAN) news were published by: Marketwatch.com which released: “0.92” on August 03, 2014, also Nasdaq.com with their article: “Zosano Pharma Corp (ZSAN) President, CEO Konstantinos Alataris Bought $168153 …” published on August 23, 2016, Globenewswire.com published: “Zosano Pharma Announces Sale of Non-Strategic Asset” on November 22, 2016. More interesting news about Zosano Pharma Corp (NASDAQ:ZSAN) were released by: Globenewswire.com and their article: “Zosano Pharma Announces US Patent Office Publication of “Method of Rapidly …” published on August 28, 2017 as well as Globenewswire.com‘s news article titled: “Zosano Pharma to Host Conference Call on Second Quarter 2017 Financial Results …” with publication date: August 02, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.